Side-by-side · Research reference
LL-37vsMOTS-c
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BAnimal-StrongHUMAN-REVIEWED16/68 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
01Mechanism of Action
Parameter
LL-37
MOTS-c
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
MOTS-c
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Standard dose
—
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
Frequency
—
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Lower / starter dose
—
2.5–5 mg / week
Recommended due to limited human data.
Duration
—
4–12 weeks (experimental)
Optimal cycle length unknown.
Reconstitution
—
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Timing
—
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Half-life
—
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
03Metabolic / Fat Loss Evidence
Parameter
LL-37
MOTS-c
Primary fat target
—
Diet-induced / metabolic obesity; systemic fat utilization
Quantified reduction
—
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
IGF-1 impact
—
No direct IGF-1 pathway; AMPK-mediated
Effect on lean mass
—
High dose significantly ↑ lean mass in mice
Triglycerides
—
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
Effect reversibility
—
Unknown — no long-term follow-up data
Key publication
—
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
04Side Effects & Safety
Parameter
LL-37
MOTS-c
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Injection site reaction
—
Mild irritation (reported)
Fluid retention / Edema
—
Not reported
Cardiovascular
—
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
Cancer risk
—
Contradictory data — some models suggest pro-proliferative effects
CNS / Neurological
—
Insomnia, headache (anecdotal reports)
GI symptoms
—
Nausea, stomach discomfort (reported)
Antibody formation
—
No data (no long-term human trials)
Pregnancy / OB
—
Avoid — insufficient safety data
Evidence quality
—
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
Absolute Contraindications
LL-37
—MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
05Administration Protocol
Parameter
LL-37
MOTS-c
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
4. Storage
—
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
5. Needle
—
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
06Stack Synergy
LL-37
— no documented stacks
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction